RHT Share Price Performance
AU$0.057
0.02 (46.15%)
31.3% undervalued intrinsic discount
AU$0.083
Fair Value
Price AU$0.057
dang AU$0.083
Fair ValueAU$0.083
Share Pricen/a
Resonance Health Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
RHT Community Narratives
DA
Fair Value
·Fair Value AU$0.083 31.3% undervalued intrinsic discount
Resonance Health will triple revenue growth to 30.83% in five years
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Resonance Health will triple revenue growth to 30.83% in five years
Resonance Health is a Perth-based medical imaging company that just delivered the most important result in its 20-year listed history. FY26 revenue rose 42% to $15.8M, net profit swung to $1.5M from a $1.7M loss, and the company generated positive operating cash flow in every single quarter.Read more
Trending Discussion
No trending discussion available.
Recently Updated Narratives
DA
Resonance Health will triple revenue growth to 30.83% in five years
Fair Value: AU$0.083 31.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Resonance Health Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 0.0016
- 100.00%
- 5.56%
- 24.6%
About RHT
- Founded
- 1987
- Employees
- n/a
- CEO
- WebsiteView website
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading. It also provides phantoms comprising FerriScan, R2*/T2*, T1CMR, and T2CMR phantoms for the calibration of MRI machines. In addition, the company operates as an imaging contract research organization that provides comprehensive proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors. It serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
